BPMC Blueprint Medicines
- 100.830
- -0.560-0.55%
- 100.830
- 0.0000.00%
Blueprint Medicines News
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Mixed Efficacy and Safety Profiles Lead to Hold Rating for Blueprint Medicines and Cogent Biosciences
A Quick Look at Today's Ratings for Blueprint Medicines(BPMC.US), With a Forecast Between $105 to $135
Blueprint Medicines Analyst Ratings
Wells Fargo Maintains Overweight on Blueprint Medicines, Lowers Price Target to $151
A Quick Look at Today's Ratings for Blueprint Medicines(BPMC.US), With a Forecast Between $105 to $155
Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $133
Needham Reiterates Buy on Blueprint Medicines, Maintains $133 Price Target
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Blueprint Medicines Price Target Announced at $88.00/Share by UBS
Blueprint Medicines Analyst Ratings
Blueprint Medicines Initiated With a Neutral at UBS
Piper Sandler Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Raises Target Price to $109
Morgan Stanley Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $120
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Stifel Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $155
Analysts' Opinions Are Mixed on These Healthcare Stocks: Blueprint Medicines (BPMC), Adaptimmune Therapeutics (ADAP) and Ardelyx (ARDX)
Blueprint Medicines Analyst Ratings
Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133
TD Cowen Maintains Blueprint Medicines(BPMC.US) With Buy Rating
Analysis
Price Target
No Data
No Data
